Dr. Tsai is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
75 Francis Street Pbb Clinics 3
Brigham And Women's Hospital Pulmonary Division
Boston, MA 02115Phone+1 617-732-5500
Education & Training
- Massachusetts General Hospital/BIDMC/Harvard Medical SchoolFellowship, Pulmonary Disease and Critical Care Medicine, 2001 - 2003
- Brigham and Women's HospitalResidency, Internal Medicine, 1997 - 2000
- Harvard Medical SchoolClass of 1997
Certifications & Licensure
- CA State Medical License 2000 - 2025
- MA State Medical License 1999 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Pulmonary Disease
Clinical Trials
- A Phase 1 TP-271 Oral PK Multiple Ascending Dose Study Start of enrollment: 2018 Mar 20
Publications & Presentations
PubMed
- 24 citationsRandomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eravacycline.Joseph V. Newman, Jian Zhou, Sergey Izmailyan, Larry Tsai
Antimicrobial Agents and Chemotherapy. 2018-10-24 - 52 citationsEpithelial cell apoptosis causes acute lung injury masquerading as emphysema.Majd Mouded, Eduardo E. Egea, Matthew J. Brown, Shane M. Hanlon, A. McGarry Houghton
American Journal of Respiratory Cell and Molecular Biology. 2009-02-02 - 20 citationsPrognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial.Jennifer Tom, Min Bao, Larry W. Tsai, Aditi Qamra, David Summers
Critical Care Medicine. 2021-10-12
Journal Articles
- Tocilizumab in Hospitalized Patients with Severe Covid-19 PneumoniaIvan O Rosas, Ronaldo C Go, Ivor S Douglas, Larry Tsai, Atul Malhotra, The New England Journal of Medicine
Press Mentions
- Tetraphase Pharmaceuticals Announces Corporate Reorganization Aimed at Maximizing XERAVA™ (Eravacycline) Commercial OpportunityJune 12th, 2019
- Tetraphase Pharmaceuticals Announces New XERAVA™ (Eravacycline) Data at the 39June 10th, 2019
- Weekly Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Ratings on Dec 15, 2018December 15th, 2018
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: